Menu Search Donate
NICU guideline identifier

Immunisation - Prevenar

This document is only valid for the day on which it is accessed. Please read our disclaimer.

Prevenar

A thirteen-valent pneumococcal conjugate vaccine (PCV13)

Interval between doses

  • Recommended 6 weeks 
  • Minimum of 4 weeks 

Effectiveness

  • Highly effective against vaccine serotype invasive disease in healthy children1 
  • Unlike the previous (polysaccharide) vaccine, it induces immunity in infants 

Pneumococcus (Steptococcus pneumoniae) 

  • Lance shaped gram positive cocci in pairs 
  • Transmission from person to person by droplet contact 
  • Ensure parent has had the Immunisation Choices pamphlet to read. 
  • Parent countersigns and also prints last name underneath signature on "once only" page of medication chart indicating consent after discussion with Dr/NS-ANP. 

When to administer to baby

  • Prevenar 13 is given at 6 weeks of age regardless of baby's weight. (The very young are at the greatest risk from pertussis and Hib). See Contraindications and Special Precautions and adverse reactions
  • Baby must be nursed on apnoea mattress for 24 hours after vaccine given and vaccine given at least 24 hours prior to discharge. 

Storage of vaccine

See Cold Chain Management guideline.

Giving vaccine

Click here for details of drawing up, giving and documentation of vaccine. 

References

  1. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368: 1495-502. 
  2. Immunisation Handbook 2014. Ministry of Health: Wellington

Did you find this information helpful?

Document Control

  • Date last published: 01 September 2015
  • Document type: Clinical Guideline
  • Services responsible: Neonatology
  • Owner: Newborn Services Clinical Practice Committee
  • Editor: Sarah Bellhouse
  • Review frequency: 2 years